Oral platinum analogue JM216, a radiosensitizer in oxic murine cells

References

• ALVAREZ, V., COBREROS, G., HERAS, A. and LOPEZ ZUMEL, C., 1978, Studies on cis-dichlorodiammineplatinum (H) as a radiosensitizer. British Journal of Cancer, 37, 68–72.
   Google Scholar
• ANDREWS, P. A., SCHIEFER, M. A., MURPHY, M. P. and HOWELL, S. B., 1988, Enhanced potentiation of cisplatin cytotox-icity in human ovarian carcinoma cells by prolonged glutathione depletion. C hem ico- Biological Interactions, 65, 51–58.
   PubMed Web of Science ®Google Scholar
• BEGG, A. C., 1990, Cisplatin and radiation: interaction probabil-ities and therapeutic possibilities. International Journal of Radiation Oncology, Biology, Physics, 19, 1183–1189.
   PubMed Web of Science ®Google Scholar
• BEGG, A. C., STEWART, F. A., DEWIT, L. and BARTELINK, H., 1990, Interactions between cisplatin and radiation in experimental rodent tumors and normal tissues. In Antitumor Drug—Radiation Interactions, edited by B. T. Hill and A. S. Bellamy (Florida: CRC Press, Boca Raton), pp. 153–170.
   Google Scholar
• BEGG, A. C., STEWART, F. A., DEWIT, L. and BARTELINK, H., 1988, Cisplatin-radiation interactions in tumours and normal tissues. In Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy, edited by M. Nicolini (Boston: Martinus Nijhoff), pp. 74–80.
   Google Scholar
• BEGG, A. C., VAN DER KOLK, P. J., DEWIT, L. and BARTELINK, H., 1986, Radiosensitization by cisplatin of RIF1 tumour cells in vitro. International J ournal of Radiation Biology, 50, 871–884.
   Web of Science ®Google Scholar
• BEGG, A. C., VAN DER KOLK, P. J., EMONDT, J. and BARTELINK, H., 1987b, Radiosensitization in vitro by cis-dia mmine(1,1 -cyclobutanedicarb oxylato) platinum (II) (Carboplatin, JM8) and ethylenediammine-malonato-platinum(II) ( JM 40). Radiotherapy and Oncology, 9, 157–165.
   PubMedGoogle Scholar
• BYFIELD, J. E. and CALABRO-JONES, P. M., 1981, Carrier-dependent and carrier-independent transport of anti-cancer alkylating agents. Nature, 294, 281–283.
   Google Scholar
• BYHARDT, R. W., SCOTT, C. B., ETTINGER, D. S. and CURRAN, W. J., 1995, Concurrent hyperfractionated irradiation and chemotherapy for unresectable non small cell lung cancer. cancer, 75, 2337–2344.
   PubMedGoogle Scholar
• CHEN, G., FREI, E. and ZELLER, W. J., 1989, Determination of intracellular reduced glutathione and glutathione related enzyme activities in cisplatin-sensitive and resistant experimental ovarian carcinoma cell lines. Cancer Letters, 46, 207–211.
   PubMedGoogle Scholar
• CHOUGULE, P. B., SUK, S., CHU, Q. D. and LEONE, L., 1994, Cisplatin as a radiation sensitizer in the treatment ofadvanced head and neck cancers. cancer, 74, 1927–1932.
   PubMedGoogle Scholar
• CLARK, E. P. and EPP, E. R., 1983, The role of thiols in cellular response to radiation and drugs. Radiation Research, 95, 437–455.
   PubMedGoogle Scholar
• DE POOTER, C. M. J., SCALLIET, P. G., ELST, H. J. and HUYBRECHT, J. J., 1991, Resistance patterns between cis-diamminedichloroplatinum(II) and ionizing radiation. Cancer Research, 51, 4523–4527.
   Google Scholar
• DOUPLE, E. B., O'HARA, J. A. and WANG, H., 1995, Production of DNA double-strand breaks by interactions between carboplatin and radiation: a potential mechanism of radiopotentiation. Radiation Research, 143, 309–315.
   Google Scholar
• DOUPLE, E. B. and RICHMOND, R. C., 1982, Enhancement of the potentiation of radiotherapy by platinum drugs in a mouse tumor. International Journal of Radiation Oncology, Biology, Physics, 8, 501–503.
   PubMedGoogle Scholar
• EICHHOLTZ-WIRTH, H. and HIETEL, B., 1994, Cisplatin resistance in mouse fibrosarcoma cells after low-dose irradiation in vitro and in vivo. British Journal of Cancer, 70, 579–584.
   PubMed Web of Science ®Google Scholar
• ELLMAN, G. L., 1959, Tissue sulfhydryl groups. Archives of Biochemistry and Biophysics, 82, 70–77.
   PubMed Web of Science ®Google Scholar
• FICHTINGER-SCHEPMAN, A. M. J., VAN DIJK-KONIJNENBURG, H. C. and DDT, F. J., 1994, Effects of thiourea and ammonium bicarbonate on the formation and stability of bifunctional cisplatin-DNA adducts: consequences for the accurate quantification of adducts in (cellular) DNA. Journal of Inorganic Biochemistry, 58, 177–191.
   Google Scholar
• GATELY, D. P. and HOWELL, S. B., 1993, Cellular accumulation of the anticancer agent cisplatin: a review. British Journal of Cancer, 67, 1171–1176.
   PubMed Web of Science ®Google Scholar
• ISMICAWA, T. and Au-OsmAN, F., 1993, Glutathione-associated cis-diamminedichloroplatinum (II) metabolism and ATP-dependent efflux from leukemia cells. Journal of Biological Chemistry, 268, 20116–20125.
   Google Scholar
• KALLMAN, F. R., PAPACCHIETTA, D. and ZAGHLOUL, M. S., 1991, Schedule-dependent therapeutic gain from the com-bination of fractionated irradiation plus cDDDP and 5-FU or plus cDDP and cyclophosphamide in C3H/Km mouse model systems. International Journal of Radiation Oncology, Biology, Physics, 20, 227–232.
   PubMedGoogle Scholar
• KELLAND, L. R., ABEL, G., MCKEAGE, M. J. and JONES, M., 1993, Preclinical antitumor evaluation of bis-acetato-ammine-dichlor-cyclohexylamine Platinum (IV): orally active platinum drug. Cancer Research, 53, 2581–2586.
   PubMed Web of Science ®Google Scholar
• KELLAND, L. R. and MCKEAGE, M. J., 1994, New platinum agents. A comparison in ovarian cancer. Drugs and Aging, 5, 85–95.
   PubMed Web of Science ®Google Scholar
• KNOX, R. J., FRIEDTos, F., LYALL, D. A. and ROBERTS, J. J., 1986, Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum(H) and cis-diammine-(1,1-cyclobutanedicarboxylato) plati-num(II) differ only in their kinetics of their reaction with DNA. Cancer Research, 46, 1972–1979.
   PubMed Web of Science ®Google Scholar
• LOWRY, O.H., ROSENBROUGH, N. J., FARR, A. L. and RANDALL, R. J., 1951, Protein measurement with folin phenol reagent. Journal of Biological Chemistry, 193, 265–275.
   PubMed Web of Science ®Google Scholar
• MCKEAGE, M. J., MISTRY, P., WARD, J. and BOXALL, F. E., 1995, A phase I and pharmacology study of an oral platinum complex, JM216: dose-dependent pharmaco-kinetics with single-dose administration. Cancer Chemotherapy and Pharmacokinetics, 36, 451–458.
   PubMed Web of Science ®Google Scholar
• MELLISH, K. J., BARNARD, C. F. J., MURRER, B. A. and KELLAND, L. R., 1995, DNA-binding properties of novel cis- and trans platinum-based anticancer agents in 2 human ovarian carcinoma cell lines. International J ournal of Cancer, 62, 717–723.
   Google Scholar
• MUGGIA, F. M., 1991, Introduction: Cisplatin update. Seminars in Oncology, 18, 1–4.
   Web of Science ®Google Scholar
• O'HARA, J. A., DOUPLE, E. B. and RICHMOND, R. C., 1986, Enhancement of radiation-induced cell kill by platinum complexes (carboplatin). Journal of Radiation Oncology, Biology, Physics, 12, 1419–1422.
   Google Scholar
• ORTA, T., EADY, J. J., PEACOCK, J. H. and STEEL, G. G., 1995, Glutathione manipulation and the radiosensitivity of human tumor and fibroblast cell lines. International journal of Radiation Biology, 68, 413–419.
   PubMed Web of Science ®Google Scholar
• PITCHARD, R. S. and ANTHONY, S. P., 1996, Chemotherapy plus radiotherapy compared with radiotherapy alone in the treatment of locally advanced, unresectable, non-small cell lung cancer. Annals of Internal Medicine, 125, 723–729.
   PubMedGoogle Scholar
• RAYNAUD, F. I., MISTRY, P., DONAGHAU, A., POON, G. K., KELLAND, L. R., BARNARD, C. F., MuRRER, B. A. and HARRAP, K. R., 1996a, Biotransformation of the platinum drug JM216 following oral administration to cancer patients. Cancer Chemotherapy and Pharmacology, 38, 155–162.
   PubMed Web of Science ®Google Scholar
• RAYNAUD, F. I., ODELL, D. E. and KELLAND, L. R., 1996b, Intracellular metabolism of the orally active platinum drug JM216: influence of glutathione levels. British J ournal of Cancer, 74, 380–386.
   PubMed Web of Science ®Google Scholar
• ROSENBERG, B., 1985, Fundamental studies with cisplatin. Cancer, 55, 2303–2316.
   PubMed Web of Science ®Google Scholar
• SAWAYA, R., TOFILON, P. J., MOHANAM, S. and ALI-OSMAN, F., 1994, Induction of tissue-type plasminogen activator and 72-kDa type-IV collagena se by ionizing radiation in rat astrocytes. International Journal of Cancer, 56, 214–218.
   Google Scholar
• SCHAAKE-KONING, C., VAN DEN BOGEART, W., DALESIO, 0. and FESTEN, J.7 1992, Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell-lung cancer. New England Journal of Medicine, 326, 524–530.
   Google Scholar
• SCHUSTER-UITTERHOEVE, L., VAN DE VAART, P. J. M., SCHAAKE-KONING, C. and BENRAADT, J.71996, Feasibility of escalat-ing daily doses of cisplatin in combination with acceler-ated radiotherapy in non small cell lung cancer. European Journal of Cancer, 32A, 1314–1319.
   Google Scholar
• SKOV, K. and MACPHAIL, S., 1991, Interaction of platinum drugs with clinically relevant x-ray doses in mammalian cells: a comparison of cisplatin, carboplatin, iproplatin, and tetraplatin. International Journal of Radiation Oncology, Biology, Physics, 20, 221–225.
   PubMed Web of Science ®Google Scholar
• TEICHER, B. A. and HOLDEN, S. A, 1987, Antitumor and radiosensitizing activity of several platinum-(+ ) dye com-plexes. Radiation Research, 109, 58–67.
   PubMed Web of Science ®Google Scholar
• TERHEGGEN, P. M. A. B., EMONDT, J. Y FLOOT, B. G. J. and DIJKIVIAN, R., 1990, The correlation between cell killing by cis-diamminedichloroplatinum(II) in six mammalian cell lines and binding of a cis-diamminedichloro-platinu m (II)-D NA antiserum. Cancer Research, 50, 3556–3561.
   Google Scholar
• TERHEGGEN, P. M. A. B., FLOOT, B. G. J., LEMPERS, E. L. M., VAN TELLINGEN, 0., BEGG, A. C. and DEN ENGELSE, L., 1991, Antibodies against cisplatin-modified DNA and cisplatin-modified (di)nucleotides. Cancer Chemotherapy and Pharmacology, 28, 185–191.
   Google Scholar
• TERHEGGEN, P. M. A. B., FLOOT, B. G. J., SCHERER, E. and BEGG, A. C., 1987, Immunocytochemical detection of interaction products of cis-diamminedichloroplatinum(II) and cis-diammine(1,1 cyclobutanedicarboxylato) platinum-(II) with DNA in rodent tissue sections. Cancer Research, 47, 6719–6725.
   Google Scholar
• TWENTYMAN, P. R., BROWN, J. M., GRAY, J. W. and FRANK°, A. J., 1980, A new mouse tumor model system (RIF-1) for comparison of endpoint studies. Journal of the National Cancer Institute, 64, 595–604.
   Google Scholar
• TWENTYMAN, P. R., KALLMAN, R. F. and BROWN, J. M.7 1979, The effect of time between X-irradiation and chemother-apy on the growth of three solid mouse tumours III is-dia m minedc hlo ro p latinu m. International J ournal of Radiation Oncology, Biology, Physics, 5, 1365–1367.
   PubMed Web of Science ®Google Scholar
• WEITBERG, A. B., YASHAR, J., GLICKSMAN, A. Sand POSNER, M.7 1993, Combined modality therapy for stage IIIA non-small cell carcinoma of the lung. European Journal of Cancer, 29A, 511–512.
   Google Scholar
• YANG, L. X., DOUPLE, E. B., O'HARA, J. A. and CRABTREE, R. A., 1995, Enhanced radiation-induced cell killing by carboplatin in cells of repair-proficient and repair-deficient Cell lines. Radiation Research, 144, 230–236.
   Google Scholar
• YANG, L. X., DOUPLE, E. B., O'HARA, J. A. and WANG, F1.7 1995, Production of DNA double-strand breaks by inter-actions between carboplatin and radiation: a potential mechanism of radiopotentiation. Radiation Research, 143, 309–315.
   Google Scholar